Related Experiment Video
Updated: May 8, 2026
07:13
Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Pralatrexate pharmacology and clinical development
Enrica Marchi1, Michael Mangone, Kelly Zullo
1Authors' Affiliations: Department of Medicine, Center for Lymphoid Malignancies, Columbia University Medical Center; and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York.
Summary
Pralatrexate is an effective antifolate drug for T-cell lymphoma. Combination therapies with pralatrexate show promise for improving treatment outcomes in lymphoid malignancies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Folates are essential for cellular proliferation, and antifolates are effective cancer therapeutics.
- Developing novel antifolates has been challenging, with limited success over decades.
Purpose of the Study:
- To evaluate the efficacy of pralatrexate, an antifolate analog with high affinity for the reduced folate carrier.
- To explore the synergistic effects of pralatrexate in combination with other chemotherapeutic agents for lymphoid malignancies.
Main Methods:
- Pralatrexate was investigated for its activity in T-cell lymphoma and other lymphoid malignancies.
- Combination studies were conducted to assess synergy between pralatrexate and agents like gemcitabine, romidepsin, and bortezomib.
Main Results:
- Pralatrexate demonstrated high activity in T-cell lymphoma, including chemotherapy-resistant cases.
- Pralatrexate exhibits significant synergy when combined with gemcitabine, histone deacetylase inhibitors, and bortezomib.
Conclusions:
- Pralatrexate is a potent agent for lymphoid malignancies, particularly T-cell lymphoma.
- Emerging combination studies suggest pralatrexate-based regimens could offer improved outcomes and challenge current treatments like CHOP.
More Related Videos
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...